Alliance Global Partners raised the firm’s price target on InspireMD to $5.20 from $4.75 and keeps a Buy rating on the shares after the company reported Q2 results ahead of the firm’s expectations. The increased target is driven by rolling its valuation multiple onto the firm’s newly-introduced 2026 estimates, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSPR:
- InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
- InspireMD reports Q2 EPS (24c) vs. (59c) last year
- NSPR Upcoming Earnings Report: What to Expect?
- InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
- InspireMD completes enrollment in C-Guardians IDE clinical trial
